Protagonist Therapeutics, Inc. (PTGX) News
Filter PTGX News Items
PTGX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PTGX News Highlights
- PTGX's 30 day story count now stands at 3.
- Over the past 4 days, the trend for PTGX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- PH are the most mentioned tickers in articles about PTGX.
Latest PTGX News From Around the Web
Below are the latest news stories about PROTAGONIST THERAPEUTICS INC that investors may wish to consider to help them evaluate PTGX as an investment opportunity.
Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ...In a notable insider transaction, President and CEO PATEL DINESH V PH D has sold 75,000 shares of Protagonist Therapeutics Inc (NASDAQ:PTGX), a clinical-stage biopharmaceutical company. |
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative ColitisNEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to ... |
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety SignalsLong term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia veraAnalysis of PACIFIC Phase 2 study shows that rusfertide improves ... |
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with DeucravacitinibThe ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or IGA 0 or 1Protagonist eligible to receive $115 million milestone upon achieving the co-primary endpoints in any ... |
Protagonist Therapeutics Reports Granting of Inducement AwardsNEWARK, CA / ACCESSWIRE / November 16, 2023 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 15, 2023, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer ... |
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most OnMaybe you could find out which stocks a well-known company that has been successful for a long time really likes -- a company such as Johnson & Johnson (NYSE: JNJ). Here are the three stocks that J&J is betting the most on. As of Sept. 30, 2023, Johnson & Johnson's biggest investment was in Legend Biotech (NASDAQ: LEGN). |
Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)NEWARK, CA / ACCESSWIRE / November 9, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) today announced it ranked in the top 3% of the 2023 Deloitte Technology Fast 500TM, a list of the fastest-growing technology, media, telecommunications, life sciences, ... |
Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect?The consensus price target hints at a 141.1% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Protagonist Therapeutics Inc (PTGX) Reports Q3 2023 Financial ResultsCompany advances with clinical development program and maintains strong cash position |
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateFive rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023)Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first- and only-in-class oral ... |